Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.

Langenberg, Marlies H G; Witteveen, Petronella O; Roodhart, Jeanine M; Verheul, Henk M W; Mergui-Roelvink, Marja; van der Sar, Jana; Brendel, Erich; Laferriere, Nicole; Schellens, Jan H M; Voest, Emile E

Langenberg, Marlies H G; Witteveen, Petronella O; Roodhart, Jeanine M; Verheul, Henk M W; Mergui-Roelvink, Marja; van der Sar, Jana; Brendel, Erich; Laferriere, Nicole; Schellens, Jan H M; Voest, Emile E.

Affiliation

Langenberg MH; Department of Medical Oncology, University Medical Center Utrecht and Science Faculty, Department Pharmaceutical Sciences, Division Drug Toxicology, Utrecht University, Utrecht, the Netherlands.

Clin Cancer Res ; 16(7): 2187-97, 2010 Apr 01.

Article in En | MEDLINE | ID: mdl-20233884

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridazines / Pyridines / Camptothecin / Deoxycytidine / Fluorouracil / Neoplasms Type of study: Clinical_trials Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2010 Document type: Article Affiliation country: Países Bajos Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google